Phase 2 N=37 Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
Childhood Glaucoma
Primary: Percentage of Eyes With Response — 33 eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=152 Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Pediatric Glaucoma · Elevated IOP in Pediatric Patients · Ocular Hypertension in Pediatric Patients
Primary: Mean Change From Baseline in IOP at Month 3 — -5.4; -5.3 mmHg
Phase 3 N=139 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Glaucoma
Primary: Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF) — 5.72; 7.18 mmHg
N/A N=110 Infrared Choroidal Reflectance Camera for the Detection of Childhood Cataract
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes
N/A N=900 Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma · Diabetic Retinopathy · Refractive Errors
Primary: Percentage of Participants That Adhere to Referral Appointment — 80; 92 Participants
N/A N=175 Long-Term Non-Interventional Latanoprost Study
Glaucoma · Ocular Hypertension
Primary: Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent) — 0.25; -0.07; 0.01; 0.04 logMar — p=0.1126
Phase 4 N=59 Use of Bevacizumab in Trabeculectomy Surgery
Glaucoma · Optic Neuropathy · Fibrosis
Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05
Phase 1 N=25 Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Glaucoma · Ocular Hypertension
Primary: Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax) — 0.0256; 0.0471; 0.0258; 0.0109 ng/mL
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
N/A N=37 Does Glaucoma Cause Loss of Brain Function?
Glaucoma
Primary: Absolute Brain Volume (Size) — 3067; 2302 cubic millimeters (mm3)
Phase 4 N=52 Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Glaucoma
Primary: Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma — 9; 12 participants
N/A N=161 How Has Glaucoma Affected Your Quality of Life?
Glaucoma · Quality of Life
Primary: Quality of Life With NEI VFQ-25 — 82.9; 82.7; 82.8; 83.0 units on a scale
N/A N=906 Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
Glaucoma · Glaucoma Suspect · Diabetic Retinopathy
Primary: Fundus Camera Images Via Telemedicine — 355; 384; 167 Participants
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
N/A N=114 Infant Aphakia Treatment Study (IATS)
Congenital Cataract
Primary: Visual Acuity — 0.80; 0.97 logMAR units — p=0.19
N/A N=318 Improving Quality Vision Outcomes in Managed Care Setting While Reducing Cost by Use of Accurate, Automated Screening
Amblyopia · Strabismus
Primary: Detection of Amblyopia and Strabismus in Children Ages 2-5 Using Automated Pediatric Vision Scanner Device — 6; 249; 0; 45 Participants
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
Phase 2 N=119 Ahmed Glaucoma Valve Surgery With Mitomycin-C
Glaucoma · Primary Open Angle Glaucoma · Secondary Glaucoma
Primary: Intraocular Pressure After Surgery — 13.1; 16.2 mmHg
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Phase 4 N=30 Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Angle-closure Glaucoma
Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
N/A N=4 Health Coaching for Glaucoma Patients
Glaucoma
Primary: Glaucoma Medication Adherence — 72 percentage of adherence time
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 1 N=1 Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.
Retinal Degeneration · Primary Open-angle Glaucoma
Primary: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) — 1 Participants
N/A N=49 Systemic Glutathione Level in Normal Tension Glaucoma
Normal Tension Glaucoma
Primary: Total Glutathione Levels — 524.02; 586.06 nmol
N/A N=146 Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old
Amblyopia
Primary: Mean Amblyopic Eye Visual Acuity Improvement With Spectacles — 2.3; 3.2 logMAR units
Phase 3 N=426 A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure at Week 1 — 19.0; 19.1; 18.0; 18.2 mmHg
Phase 4 N=17 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
Glaucoma
Primary: Pre-Treatment IOP (Intraocular Pressure) — 21.8 mm Hg